Nutrients in Alzheimer's Disease: The Interaction of Diet, Drugs and Disease

被引:6
|
作者
Liyanage, S. Imindu [1 ]
Vilekar, Prachi [1 ]
Weaver, Donald F. [1 ,2 ]
机构
[1] Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada
[2] Univ Toronto, Fac Med, Toronto, ON, Canada
关键词
Alzheimer's disease; Diet; Clinical trials; Medications; Lipids; Cholesterol; Sugar; Vitamins; Minerals; Microbiota; AMYLOID PRECURSOR PROTEIN; MEDITERRANEAN DIET; GUT MICROBIOTA; COGNITIVE IMPAIRMENT; THIAMINE-DEFICIENCY; OXIDATIVE STRESS; APOLIPOPROTEIN-E; BETA-PROTEIN; NEURODEGENERATIVE DISEASES; DOCOSAHEXAENOIC ACID;
D O I
10.1017/cjn.2018.353
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In recent decades, clinical trials in Alzheimer's disease (AD) have failed at an unprecedented rate. The etiology of AD has since come under renewed scrutiny, both to elucidate the underlying pathologies and to identify novel therapeutic strategies. Here, diet has emerged as a potential causative/protective agent. A variety of nutrients, including lipids, minerals, vitamins, antioxidants and sugars as well as broader dietary patterns and microbiotal interactions have demonstrated associations with AD. Although clinical trials have yet to definitively implicate any singular dietary element as therapeutic or causative, it is apparent that dietary preferences, likely in complex synergies, may influence the risk, onset and course of AD. This review catalogs the impact of major dietary elements on AD. It further examines an unexplored reciprocal association where AD may modulate diet, as well as how potential therapeutics may complicate these interactions. In doing so, we observe diet may have profound effects on the outcome of a clinical trial, either as a confounder of a drug/disease interaction or as a generally disruptive covariate. We therefore conclude that future clinical trials in AD should endeavor to control for diet, either in study design or subsequent analyses.
引用
收藏
页码:23 / 34
页数:12
相关论文
共 50 条
  • [21] GABAergic drugs and Alzheimer's disease
    Limon, Agenor
    Reyes-Ruiz, Jorge Mauricio
    Miledi, Ricardo
    FUTURE MEDICINAL CHEMISTRY, 2011, 3 (02) : 149 - 153
  • [22] Statins:: drugs for Alzheimer's disease?
    Eckert, GP
    Wood, WG
    Müller, WE
    JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (08) : 1057 - 1071
  • [23] Drugs for the treatment of Alzheimer's disease
    Mashkovskii M.D.
    Glushkov R.G.
    Pharmaceutical Chemistry Journal, 2001, 35 (4) : 179 - 182
  • [24] Review of drugs for Alzheimer's disease
    Sun, Xiaoting
    Jin, Lan
    Ling, Peixue
    DRUG DISCOVERIES AND THERAPEUTICS, 2012, 6 (06): : 285 - 290
  • [25] Drugs for treatment of Alzheimer's disease
    Wilkinson, D
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2001, 55 (02) : 129 - 134
  • [26] Statins: drugs for Alzheimer’s disease?
    G. P. Eckert
    W. G. Wood
    W. E. Müller
    Journal of Neural Transmission, 2005, 112 : 1057 - 1071
  • [27] Epigenetic drugs for Alzheimer's disease
    Peedicayil, Jacob
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (04) : 1152 - 1153
  • [28] Drugs for imaging Alzheimer's disease
    Baranowska-Kortylewicz, J.
    Kortylewicz, Z.
    Nearman, J.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (05) : 830 - 830
  • [29] Stimulating drugs in Alzheimer's disease
    Stewart, A
    MOLECULAR MEDICINE TODAY, 1997, 3 (10): : 414 - 415
  • [30] The Use of Neuroimaging to Assess Associations Among Diet, Nutrients, Metabolic Syndrome, and Alzheimer's Disease
    Pistollato, Francesca
    Sumalla Cano, Sandra
    Elio, Inaki
    Masias Vergara, Manuel
    Giampieri, Francesca
    Battino, Maurizio
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 48 (02) : 303 - 318